Skip to main content

LEGN Legend Biotech Corporation

Healthcare

18.62

Close 10/9

Open
18.78
High
19.06
Low
18.55
Prev close
18.71
Volume
1.4M
52W 16.24 37.46
Loading candles…

Is Legend Biotech Corporation a buy? Fundamentals and valuation first

As of 2026-10-09

Growth: Strong.

Quality Neutral All 3 indicators are Average.
ROE, TTM (%) -7.45 31th percentile Average
Operating margin, TTM (%) -4.42 29th percentile Average
FCF margin, TTM (%) -20.1 21th percentile Average
Growth Strong Revenue growth, TTM YoY is Top.
Revenue growth, TTM YoY (%) 59.54 89th percentile Top
Momentum Neutral All 2 indicators are Average.
60-day return (%) -18.01 25th percentile Average
240-day return (%) -41.56 21th percentile Average
Risk / liquidity Neutral 20-day dollar volume is Good, but 60-day annualized volatility is Average.
20-day dollar volume 41,877,924 79th percentile Good
60-day annualized volatility (%) 56.58 61th percentile Average

Legend Biotech Corporation (LEGN) today

1 quant signals active · As of 2026-10-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Legend Biotech Corporation (LEGN) peers and tracking

Watchlist

This page refreshes daily after the close. Add Legend Biotech Corporation to your watchlist to track signal changes on your next visit.

Legend Biotech Corporation (LEGN) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 59.54%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

9 historical occurrences (since 2021-08-23)
Average forward return after Filed revenue acceleration。20-day: Win 55.6%, Sample 9, Median +2.08%, Excess +0.53%, Beat mkt rate 44.4%；60-day: Win 50%, Sample 8, Median +8.47%, Excess +8.57%, Beat mkt rate 50%；120-day: Win 50%, Sample 8, Median -4.01%, Excess -9.28%, Beat mkt rate 37.5%

120 days after: historical avg -6.21%

20-day +1.25%
60-day +9.24%
120-day -6.21%
20-day
60-day
120-day
Win
55.6%
50%
50%
Sample
9
8
8
Median
+2.08%
+8.47%
-4.01%
Excess
+0.53%
+8.57%
-9.28%
Beat mkt rate
44.4%
50%
37.5%

Over 8 occurrences, 120-day forward avg declined 6.21%, lagged the market by 9.28 pts; win rate 50%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg -5.27%, win rate 25%, beating the market by -8.89 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

12 times historically; 60-day forward avg -6.64%, win rate 41.7%, beating the market by -8.67 pts on average.

Continue researching Legend Biotech Corporation with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.